TAP Partner News During ASH: Dec 2023
TAP Partner News During ASH: Dec 2023
ASH Highlights (click to learn more about each TAP partnership)
-
Affimed: clinical oral presentation of AFM13 in combination with allogeneic NK cells in CD30 HL & PTCL and poster presentation detailing Phase 2 trial in progress
-
Celator: multiple poster presentations on CPX-351 clinical results in AML, MPNs and high-risk MDS
-
Constellation: clinical oral presentation of Phase 3 MANIFEST-2 topline data in treatment-naive myelofibrosis and a poster presentation on patient-reported outcome from Phase 2 trial
-
Faron: clinical poster presentation of bexmarilimab in combo with SOC in AML and MDS
-
ImCheck: preclinical poster presentation of ICT01 to support Phase 2 expansion into 1L AML in combo with Ven/Aza
-
Immunitas: preclinical poster presentation of IMT-009 to support ongoing Phase 1 clinical trial
-
Kite: multiple oral and poster presentations of axi-cel in a variety of B-NHL indications, including FL and LBCL
-
Kura: two presentations of ziftomenib (KO-539) showcasing preclinical combination studies and a combination Phase 1 trial in progress
-
Kymera: clinical poster presentation of STAT3 degrader in TCL (PTCL and CTCL) and solid tumors and preclinical poster on combination approaches in AML
-
Ryvu: preclinical and clinical poster presentations of RVU120 in AML and MDS
-
Stemline: clinical poster presentation of tagrazofusp in CD123-positive AML
-
Vittoria: two oral and one poster presentations platform and preclinical data to support planned Phase 1 trial in TCL
Company Announcements
Immunitas Therapeutics Announces Upcoming Presentation at ASH 2023 Annual Meeting
WALTHAM, Mass., December 4, 2023 – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present new data supporting continued clinical development of its lead program IMT-009 for solid tumors and hematological malignancies at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023).
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Rare Blood Cancers at ASH 2023
DUBLIN, Nov. 30, 2023 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present six abstracts related to LLS TAP-supported Vyxeos (CPX-351) at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12.
Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting
PHILADELPHIA, Nov. 29, 2023 - Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by the Company, at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, taking place from December 9-12th, 2023, in San Diego, California.
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
WATERTOWN, Mass., Nov. 02, 2023 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that new KT-333 Phase 1 data highlighting safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses will be presented at the ASH 65th Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego, California.
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
Mannheim, Germany, November 2, 2023 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced two upcoming presentations on its lead innate cell engager (ICE®) AFM13 at the American Society of Hematology (ASH) 2023 Annual Meeting.
Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Krakow, Poland – November 2, 2023 – Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, will be presented on four posters at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 9 –12, 2023 in San Diego, California.
Faron to present Phase 1/2 data from BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
TURKU, Finland / BOSTON, Massachusetts - November 2, 2023 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs), at the 65th American Society of Hematology (ASH) Annual Meeting.
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Planegg/Munich, Germany, November 2, 2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in San Diego, California, from December 9 to 12, 2023.
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
November 2, 2023 - FOSTER CITY, Calif. & SANTA MONICA, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share presentations, including oral presentations, during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (December 9-12).